Clinical trials: Leukocyte Disorders
Vitamin D3, Chronic-granulomatous Disease
Vitamin D3 For CGD Patients With BCGosis/Itis
When children with chronic granulomatous disease (CGD) got BCG infection the treatment would be a tough task. The goal of the proposed research is to observe weather vitamin D supplementation can help the CGD children get through…
- Conditions
- Vitamin D3, Chronic-granulomatous Disease, BCG
- Trial name
- NCT03984890
- Testing
- Vitamin D3, Traditional treatment of CGD and TB
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Fudan University
Hypereosinophilic Syndrome
A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)
This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with…
- Trial name
- NATRON (NCT04191304)
- Testing
- Benralizumab
- Where
- 52 sites in United States, Argentina and 15 more
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Eosinophilic Esophagitis
Effects of Swallowed Steroids on Bone Density and Growth in Pediatric Eosinophilic Esophagitis
Eosinophilic esophagitis (EoE) is characterized by allergy-driven inflammation of the esophagus leading to a variety of gastrointestinal symptoms and increased healthcare utilization.
- Trial name
- NCT03615950
- Testing
- Bone Mineral Density (DEXA) scan, Vitamin D Measurement, Height measurement
- Where
- United States
- Sponsor
- Arkansas Children's Hospital Research Institute
Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia
Starting Granulocyte Colony-Stimulating Factor at 1 Day vs 3 Days Following Chemotherapy in Pediatric Cancer Patients
Chemotherapy places patients at an increased risk of infection. A medication called granulocyte colony-stimulating factor is given as a daily injection in order to help decrease the risk of infection.
- Conditions
- Granulocyte Colony-Stimulating Factor, Chemotherapy-induced Neutropenia, Chemotherapy-Induced Febrile Neutropenia, Pediatric Cancer
- Trial name
- NCT03823950
- Testing
- Granulocyte Colony-Stimulating Factor
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Mississippi Medical Center
Neutropenia, Fever
The Tobramycin Study
Evaluate if tobramycin given once a day is at least as efficacious as the traditional tobramycin given three times a day, given with penicillin G, til patients with febrile neutropenia.
- Conditions
- Neutropenia, Fever, Cancer
- Trial name
- NCT00257790
- Testing
- Tobramycin once a day
- Volunteers
- 210 people
- Sponsor
- Oslo University Hospital
Wiskott-Aldrich Syndrome
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
An open follow up study of patients enrolled in the Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome and treated with autologous CD34+ cells transduced with the w1.6_hWASP_WPRE…
- Trial name
- WASFUP (NCT02333760)
- Testing
- Autologous CD34+ cells transduced with WASP lentiviral vector
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Genethon
Hematologic Disease and Disorders, Donors
Screening for Hematology Branch Protocols
This study allows the evaluation of subjects in order to determine their ability to safely participate in other active research studies.
- Conditions
- Hematologic Disease and Disorders, Donors, Healthy Volunteer
- Trial name
- NCT00001620
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Eosinophilic Esophagitis
A Six Month, Safety Follow-up Study in Eosinophilic Esophagitis Subjects Who Completed Study PR-021
This purpose of this study is the long-term follow-up of glucocorticosteroid-related adverse events and hypothalamic-pituitary-adrenal axis (HPA) suppression in subjects after discontinuation of study drug received in the PR-021…
- Trial name
- NCT01498497
- Testing
- EUR-1100
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Forest Laboratories
Granulomatous Disease, Chronic, X-linked
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
Chronic Granulomatous Disease (CGD) is an inherited immunodeficiency disorder which results from defects that prevent white blood cells from effectively killing bacteria, fungi and other microorganisms.
- Trial name
- NCT02234934
- Testing
- Lentiviral G1XCGD Gene Therapy
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of California, Los Angeles
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome
Funding Source--FDA OOPD. Orphan Product Grant Number--1R01FD004091-01A1 Context: Wiskott-Aldrich syndrome (WAS) is a fatal, devastating disease with ill-defined treatment modalities, which affects young boys.
- Trial name
- WAS (NCT00774358)
- Testing
- Interleukin-2
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Soma Jyonouchi
Neutropenia, Febrile, Pediatric Cancer
Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer
The study is a nationwide, multicenter, open label, randomized controlled trial. A target population of 220 children in treatment for cancer with neutropenic fever and a neutrophil count below 0.5 × 10⁹ cells/L with expected…
- Trial name
- NCT04637464
- Testing
- Early termination of empirical antibiotics
- Where
- 3 sites in Denmark
- Volunteers
- 93 people
- Sponsor
- Kjeld Schmiegelow
Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy
Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy
Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia
- Trial name
- NCT03434795
- Where
- France
- Volunteers
- 1,900 people
- Sponsor
- University Hospital, Lille
Neutropenia, Fever
MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044)
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter…
- Trial name
- NCT00082537
- Testing
- caspofungin acetate, Comparator: AmBisome
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
OBJECTIVES: I. Provide curative immunoreconstituting allogeneic bone marrow transplantation for patients with primary immunodeficiencies. II.
- Conditions
- Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease
- Trial name
- NCT00006054
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fairview University Medical Center
PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis
Natural History of Severe Allergic Inflammation and Reactions
Background: Allergic inflammation is central to allergy-related diseases and disorders, such as asthma, food allergies, and atopic dermatitis.
- Conditions
- PGM3 Deficiency, Eosinophilic and/or Atopic Dermatitis, OSMR Deficiency, Primary Localized Cutaneous Amyloidosis
- Trial name
- NCT01164241
- Where
- United States
- Volunteers
- 945 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Esophagitis, Eosinophilic Esophagitis
Eosinophilic Esophagitis Databank
This study will establish a registry for participants with eosinophilic esophagitis (EoE) and create a research resource that will provide further insights into EoE.
- Trial name
- CoFAR5 (NCT01323803)
- Where
- 5 sites in United States
- Volunteers
- 709 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
New Phenotype (Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia)
Research Into the Molecular Bases of a New Phenotype Combining Premature White Hair, Polycystic Kidney Disease, Aortic Dilation/Dissection and Lymphopenia
This study involves a single family, including 1 patient, father, mother and sister. The patient presented with a new phenotype associating premature white hair, renal polycystosis, aortic dilation/dissection and lymphopenia.
- Trial name
- BCL-2 (NCT03651388)
- Where
- France
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Eosinophilic Esophagitis, EoE
Dupilumab for Eosinophilic Esophagitis With Severe Strictures
The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE).
- Trial name
- DESTRICT (NCT06352073)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of North Carolina, Chapel Hill
Adenosine Deaminase Deficiency
Investigation of ADA Enzyme Deficiency
This observational study was designed as a prospective epidemiological screening study. Patients who applied to the centers participating in the study and were found to be lymphopenic in at least one examination will be included…
- Trial name
- NCT05300334
- Testing
- adenosine deaminase test
- Where
- Turkey (Türkiye)
- Volunteers
- 800 people
- Sponsor
- TRPHARM
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients…
- Trial name
- NCT01270464
- Testing
- Reslizumab
- Where
- 89 sites in United States, Argentina and 11 more
- Volunteers
- 315 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.